StemCell Therapy

NEW YORK, NY--(Marketwired - May 04, 2017) - Planda Biotechnology (PLPL) announced last week that its highly bioavailable Phytofare Catechin Complex would be the active ingredient in Capital Brand's reformulated and soon-to-be released SuperFood Fat Burning Boost, which is used with the well-known brand NutriBullet. This week we learned that thanks to a deal with Coyne Healthcare -- Planda's signature brand Phytofare will make its way to the U.S. and Europe as the star ingredient in Coyne Healthcare's product Origine 8.

Coyne Healthcare placed an order for 1.2 million of Planda's Origine 8 capsules, which is a product that not only uses the highly bioavailable green tea extract, Phytofare Catechin Complex, but further enhances the bioavailability of the extract by using an advanced liposome technology developed and clinically validated to improve the delivery of nutritional substances.

Origine 8 is a product that entraps all 8 of the catechins of the tea plant, and according to Planda, it is the only catechin-based capsule on the market backed by human clinical studies that prove it has superior bioavailability.

Coyne Healthcare has already been selling Planda's unique product in South Africa, but it now expects to launch Origine 8 this month in both the U.S. and Europe. The good news for Planda is that Coyne Healthcare has forecasted sales of 10.6 million Origine 8 capsules in 2017, and Coyne expects sales to further increase to 24 million Origine 8 capsules in 2018.

Coyne makes its products (http://coynehealthcare.co.za/#products) available through pharmacies, health food stores and medical practitioners, so for both NutriBullet and Coyne Healthcare to bring Planda's signature brand to the U.S., investors will have a great opportunity to physically see their investment up close and personal.

Sales at Planda and the recognition that the company is gaining globally, is clearly a response to the efforts made by the new COO, Callum Cottrell-Duffield, well before now. He led the company's sales and marketing team in its effort to grow the brand and expand the company's footprint worldwide after Planda's signature product was available for mass production and ready to market on a much broader scale last year. His work to increase sales and marketing throughout Africa, the United States, Europe, Asia and South America by telling the Planda story, is starting to pay off now in 2017.

And, with brands like NutriBullet and Coyne Healthcare, who both use and market only the highest quality ingredients in their products, advertising the Phytofare name, it shouldn't take long for Planda to grow quite an impressive sales footprint worldwide.

About Stock Market Media Group

Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles.

We may from time to time include our own opinions about our featured companies, their businesses, markets and opportunities. Any opinions we may offer are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers and viewers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any company are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: http://www.sec.gov. We also recommend as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.

We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications are not a recommendation to buy or sell a security.

Read More

Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment. In order to be in full compliance with the Securities Act of 1933, Section 17(b), we are disclosing that SMMG is compensated $5,000 per month by Plandai Biotechnology for content development. Neither SMMG nor anyone associated with it owns shares in PLPL.

For more information: http://www.stockmarketmediagroup.com.

Here is the original post:
Plandai Biotechnology Expanding Footprint of Phytofare into U.S. with Continued Sales - Yahoo Finance

Post Analyst

Puma Biotechnology, Inc. (PBYI) held by 19 SEC 13F Filers | Post ... Post Analyst Puma Biotechnology, Inc. (NASDAQ:PBYI) reached 87.69% versus a 1-year low price of $19.74. The stock was last seen -5% lower, reaching at $37.05 on May ... NJ State Employees Deferred Compensation Plan Has $341000 Position in Puma Biotechnology Inc (PBYI)Markets Daily Puma Biotechnology Inc (PBYI) Receives Buy Rating from Stifel ...Transcript Daily Puma Biotechnology's (PBYI) Outperform Rating Reaffirmed at ...Sports Perspectives Davidson Register -Searcy News -Bibeypost.com all 11 news articles »

More here:
Puma Biotechnology, Inc. (PBYI) held by 19 SEC 13F Filers | Post ... - Post Analyst

The well-known TED Talks is a clearinghouse of big thinkers and big ideas, and quite a few of them have focused on agriculture and food production over the years.

Engineering Drought Resistance Jill Farrant, a Professor of molecular and cell biology at University of Cape Town, South Africa, is studying how ancient DNA can be turned on to help important food crops fight off drought. She and colleagues have been studying resurrection plants to achieve this goal. Resurrection plants are those that can undergo extreme drought without water for months or even years. Then when the next rain comes along within 12 to 48 hours the plants green up and start growing again.

Farrants How We Can Make Plants Survive Without Water TED Talk featured her research into how resurrection plants work and if those special characteristics could be transferred into other plants, especially food crops.

Robot Swarms Vijay Kumar, Dean of the University of Pennsylvanias School of Engineering and Applied Science, wowed his TED Talk audience with his presentation titled The Future of Flying Robots. His lab is developing autonomous flying robots that use onboard sensors, cameras, and laser scanners to map the environment it is in and avoid obstacles while navigating.

All agriculture-related TED Talks can be found at ted.com/topics/agriculture.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:TED Talks Take on Agriculture Innovation

For more background on the Genetic Literacy Project, read GLP on Wikipedia

The rest is here:
Popular TED Talks explore future of agricultural innovation, biotechnology - Genetic Literacy Project

Barron's

Northeast Financial Consultants Inc Sells 650 Shares of iShares NASDAQ Biotechnology Index (IBB) The Cerbat Gem iShares NASDAQ Biotechnology Index logo Northeast Financial Consultants Inc cut its stake in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 48.1% during the first quarter, according to its most recent disclosure with the Securities and ... iShares NASDAQ Biotechnology Index (IBB) Shares Bought by Beaumont Financial Partners LLCTranscript Daily iShares NASDAQ Biotechnology Index (IBB) Upgraded to Buy at Vetr Inc.Markets Daily iShares NASDAQ Biotechnology Index (IBB) Stake Maintained by Barrett Asset Management LLCSports Perspectives Chaffey Breeze -BBNS -Community Financial News all 28 news articles »

View original post here:
Northeast Financial Consultants Inc Sells 650 Shares of iShares NASDAQ Biotechnology Index (IBB) - The Cerbat Gem

Barron's

iShares NASDAQ Biotechnology Index (IBB) Upgraded at Vetr Inc. The Cerbat Gem iShares NASDAQ Biotechnology Index logo Vetr upgraded shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) from a hold rating to a buy rating in a research report report published on Wednesday, April 5th. They currently have $298.93 target ... iShares NASDAQ Biotechnology Index (IBB) Stake Increased by ...Markets Daily iShares NASDAQ Biotechnology Index (IBB) Rating Increased to Buy at Vetr Inc.Transcript Daily iShares NASDAQ Biotechnology Index (IBB) Stock Rating Upgraded ...Sports Perspectives Barron's -Petro Global News 24 -Chaffey Breeze all 14 news articles »

View post:
iShares NASDAQ Biotechnology Index (IBB) Upgraded at Vetr Inc. - The Cerbat Gem

Dr. Felister Makini, Deputy Director General (crops) at the Kenya Agricultural & Livestock Research Organization (KALRO), noted that African women play a critical role in ensuring food security. She urged the government to make farming easier for them by providing modern tools such as biotechnology. As African women, we are the ones who suffer most whenever drought and food shortages strike, despite the availability of technological solutions to these problems, she said. We need to speak with one voice and advocate for a predictable policy environment. I have children and a family to protect. I cannot advocate for something that I know would affect them she added.

On her part, Prof. Caroline Thoruwa, Chairperson, African Women in Science and Engineering (AWSE), noted that for Africa to advance in agri-biotech, women must be involved. It is time to tell the public about the positive side of biotechnology. We need to raise up the status of women in biotechnology and also encourage women to network in order to achieve the noble goal of sharing their science, she said.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:AFRICAN WOMEN IN BIOSCIENCES CALL FOR SUPPORTIVE POLICIES ON BIOTECHNOLOGY

For more background on the Genetic Literacy Project, read GLP on Wikipedia

Read the rest here:
Kenyan scientists push for female farmers' access to biotechnology - Genetic Literacy Project

The Cerbat Gem

Rodman & Renshaw Reiterates Buy Rating for Cellect Biotechnology Ltd. - American Depositary Shares (APOP) The Cerbat Gem Rodman & Renshaw reissued their buy rating on shares of Cellect Biotechnology Ltd. American Depositary Shares (NASDAQ:APOP) in a research report report published on Tuesday, April 4th. Rodman & Renshaw currently has a $1.00 price objective on ... Cellect Gets Green Light From FDA For ApoGraft IND Submission in the U.S.Nasdaq all 2 news articles »

Read the original post:
Rodman & Renshaw Reiterates Buy Rating for Cellect Biotechnology Ltd. - American Depositary Shares (APOP) - The Cerbat Gem

Cellect Biotechnology Ltd, based in Israel, has developed an innovative technology which enables the production of stem cells to therapies and treatments that require stem cells as the main raw material. The company trades on both the Tel Aviv Stock Exchange (TASE) and NASDAQ, and had a market capitalisation at TASE of ca. 45 million USD (prior to the release of Frost & Sullivan report today).

Frost & Sullivan publishes equity research reports on technology, biomed and healthcare companies that are listed on the TASE, within the framework of the analysis program that the TASE has initiated. Key goals of the program are enhancing global awareness of these companies and enabling more informed investment decisions by investors interested in hot Israeli hi-tech and healthcare companies.

In the coming months, Frost & Sullivan will release 9 additional initiation coverage reports, covering the other companies that have joined the programme: 6 biomed companies Aposense, Brainsway, BiolineRX, Kitov Pharmaceuticals, D.N.A. Biomedical Solutions, and Redhill Biopharma; and 3 technology companies: Safe-T Group, Vonetize and Energix Renewable Energies.

For the purpose of equity research services, Frost & Sullivan, the leading global consulting, and market research firm, will leverage relevant analysts, experts and growth consultiants among a staff of 1,800, at ca. 50 branches across 6 continents, including in Israel. Frost & Sullivan will utilize the experience and know-how accumulated over the course of 55 years in medical technologies, life sciences, technology, energy, and other industrial fields, including the publication of tens of thousands of market and technology research reports, and economic analyses and valuations.

Starting September 2016 Edison Investment Research released analyses of 11 companies, and a significant increase in trading volume and in the exposure of the companies included in the project to both the local and foreign investing public is evident. It is noteworthy that in most of the reviewed dual listings, trading volume has increased significantly both in Israel and the United States.

See the rest here:
Frost & Sullivan Publishes Initiation Coverage Report On Cellect Biotechnology - Equity Research Is Published In The ... - Exchange News Direct

May 01, 2017 07:30 ET | Source: Research and Markets

Dublin, May 01, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Animal Biotechnology - Technologies, Markets and Companies" to their offering.

This report describes and evaluates animal biotechnology and its application in veterinary medicine and pharmaceuticals as well as improvement in food production. Knowledge of animal genetics is important in the application of biotechnology to manage genetic disorders and improve animal breeding. Genomics, proteomics and bioinformatics are also being applied to animal biotechnology.

Transgenic technologies are used for improving milk production and the meat in farm animals as well as for creating models of human diseases. Transgenic animals are used for the production of proteins for human medical use. Biotechnology is applied to facilitate xenotransplantation from animals to humans. Genetic engineering is done in farm animals and nuclear transfer technology has become an important and preferred method for cloning animals.There is discussion of in vitro meat production by culture

Biotechnology has potential applications in the management of several animal diseases such as foot-and-mouth disease, classical swine fever, avian flu and bovine spongiform encephalopathy. The most important biotechnology-based products consist of vaccines, particularly genetically engineered or DNA vaccines. Gene therapy for diseases of pet animals is a fast developing area because many of the technologies used in clinical trials humans were developed in animals and many of the diseases of cats and dogs are similar to those in humans.RNA interference technology is now being applied for research in veterinary medicine

Molecular diagnosis is assuming an important place in veterinary practice. Polymerase chain reaction and its modifications are considered to be important. Fluorescent in situ hybridization and enzyme-linked immunosorbent assays are also widely used. Newer biochip-based technologies and biosensors are also finding their way in veterinary diagnostics.

Biotechnology products are approved by the Center for Veterinary Medicine of the FDA. Regulatory issues relevant to animal biotechnology are described.

Approximately 124 companies have been identified to be involved in animal biotechnology and are profiled in the report. These are a mix of animal healthcare companies and biotechnology companies. Top companies in this area are identified and ranked. Information is given about the research activities of 11 veterinary and livestock research institutes. Important 108 collaborations in this area are shown.

Share of biotechnology-based products and services in 2016 is analyzed and the market is projected to 2026.

Key Topics Covered:

Executive Summary

1. Introduction to Animal Biotechnology

2. Application of Biotechnology in Animals

3. A Biotechnology Perspective of Animals Diseases

4. Molecular Diagnostics in Animals

5. Biotechnology-based Veterinary Medicine

6. Research in Animal Biotechnology

7. Animal Biotechnology Markets

8. Regulatory issues

9. Companies Involved in Animal Biotechnology

10. References

For more information about this report visit http://www.researchandmarkets.com/research/6hlgn5/animal

Source: Jain PharmaBiotech

About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Related Articles

Research and Markets Logo

LOGO URL | Copy the link below

Formats available:

Continued here:
Animal Biotechnology Technologies, Markets and Companies 2016-2026 - GlobeNewswire (press release)

TORONTO, May 1, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, will be exhibiting at the American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference in San Diego, California.

"We are pleased to be a contributor to this very prestigious conference," said Andrew Morris, CEO of SQI Diagnostics. "This event brings together the world's leading experts and representatives from all sectors of pharma and biotechnology drug development and gives us the opportunity to share our novel multiplexing applications in drug development testing. Over the past year, we have made significant progress in our work with our pharma and biotech customers and believeour unique productswill prove to be beneficial to our customers who are large, global pharmaceutical companies.

The conference will run from May 1-3, 2017. Please stop by and visit us at booth 316.

About SQI Diagnostics

SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company's proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. For more information, please visit http://www.sqidiagnostics.com.

Contacts:

Sales and Marketing Contact: Russ Peloquin Vice President, Global Commercial Operations 913.484.9022 rpeloquin@sqidiagnostics.com

Investor Relations Contact: Andrew Morris Chief Executive Officer 416.674.9500 ext. 229 amorris@sqidiagnostics.com

Forward-looking Information

This news release contains certain forward-looking statements, including, without limitation, statements containing the words "will", "may", "expects", "intends", "anticipates" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. The forward-looking statements in this news release include without limitation, statements with respect to the Private Placement and the use of proceeds of the Private Placement. These forward-looking statements involve risks and uncertainties including, but not limited to risks related to the failure to obtain necessary regulatory and stock exchange approvals, general economic and market segment conditions, and international risk and currency exchange risks, agreements and future agreements to sell our products, the success of our Diagnostic Tools and Services business and our intent to build near-term revenue streams from this business, the successful regulatory filing and receipt of regulatory approvals for our later stage quantitative diagnostic kits, the acceleration of our revenue ramp, general economic and market segment conditions, competitor activity, technology changes and regulatory approvals. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company's ongoing filings with the securities regulatory authorities, which filings can be found at http://www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable laws.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Read More

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The rest is here:
SQI Diagnostics to Exhibit at the National Biotechnology Conference - Yahoo Finance

[Editors note: Tess Doezema is a doctoral student at the School for the Future of Innovation in Society at Arizona State University, where she researches biotechnology promise and politics.]

[S]cientists and others offer a picture of a Manichean world divided into those who are for scientific and technological progress and those who are against ita representation of the world that we have been seeing more and more of lately in reports of a war on science. But drawing this line is dangerous. The real problem here is the regulatory process itself, which forces dissent to take the narrow form of challenges to scientific data and methodology and ignores other questions about whats at stake.

Some might read the vast public preoccupation with a broad set of social, political, and economic issues as the contamination of science with politics. But I would suggest that this is actually a case of the reverse problem: seemingly endless conflict around the AquAdvantage salmon reflects the limitation of using narrow scientific terms to address questions of broad social, political, and economic significance.

Scientists often dismiss resistance to the AquAdvantage salmon and other biotechnologies as borne of scientific ignorance. But its a lot easier to understand peoples reluctance if you realize that the debate is about much broader questions than science alone can answer.

Originally posted here:
Are you 'anti-science' if you resist biotechnology on political or economic grounds? - Genetic Literacy Project

USA Commerce Daily

379,289 Shares in Puma Biotechnology Inc (PBYI) Acquired by ... The Cerbat Gem Emerald Advisers Inc. PA bought a new stake in shares of Puma Biotechnology Inc (NYSE:PBYI) during the first quarter, according to its most recent Form 13F ... Should You Buy, Sell, Or Hold? - Puma Biotechnology, Inc. (PBYI), SkyWest, Inc. (SKYW)USA Commerce Daily Emerald Mutual Fund Advisers Trust Takes Position in Puma ...BBNS Puma Biotechnology (PBYI) Getting Somewhat Negative Press ...Chaffey Breeze HugoPress -Rives Journal -W News all 17 news articles »

More:
379,289 Shares in Puma Biotechnology Inc (PBYI) Acquired by ... - The Cerbat Gem

The Newburgh Press

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Soars On Xenetic Biosciences Inc. (NASDAQ:XBIO) Distribution ... StockNewsUnion Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) continues to power high in the market on the back of a recently announced product distribution deal. A deal with Xenetic Biosciences is expected to make the company's products available on the ... Traders are Following Technical Levels for Prana Biotechnology Ltd (PRAN)Rives Journal Does Prana Biotechnology Limited (PRAN)'s current closing price competes the market?TopChronicle Notable Institutional Stake In These Stocks: Prana Biotechnology (NASDAQ:PRAN), Adamis Pharmaceuticals ...Wallstreet Investorplace TRA -The Newburgh Press -Is stories all 13 news articles »

See the original post here:
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Soars On Xenetic Biosciences Inc. (NASDAQ:XBIO) Distribution ... - StockNewsUnion